mmai mmai 5-methoxy-6-methyl-2-aminoindane (mmai) is a drug developed in the 1990s by a team led by david e. nichols at purdue university. it acts as a non-neurotoxic and highly selective serotonin releasing agent (ssra) and produces entactogen effects in humans. it has been sold as a designer drug and research chemical online since 2010. mmaiclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status in general: uncontrolled identifiers iupac name 5-methoxy-6-methyl-2,3-dihydro-1h-inden-2-amine cas number136468-19-4 ypubchem cid131575chemspider116274uniijf10u4i82pcomptox dashboard (epa)dtxsid20927886 chemical and physical dataformulac11h15nomolar mass177.247 g·mol−13d model (jsmol)interactive image smiles cc1cc2cc(n)cc2cc1oc inchi inchi=1s/c11h15no/c1-7-3-8-4-10(12)5-9(8)6-11(7)13-2/h3,6,10h,4-5,12h2,1-2h3key:jlesvlctioahpt-uhfffaoysa-n mmai has been shown to relieve stress-induced depression in rats more robustly than sertraline, and as a result it has been suggested that ssras like mmai and 4-mta could be developed as novel antidepressants with a faster onset of therapeutic action and superior efficacy to current antidepressants such as the selective serotonin reuptake inhibitors (ssris).